International Business News - Therapeutics http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Pain Therapeutics Inc. and King Pharmaceuticals Inc. said Tuesday the Food and Drug Administration granted the drug developers' pain treatment candidate Remoxy priority review. http://www.ibtimes.com/articles/20080812/pain-therapeutics-king-drug-gets-priority-review.htm Tue, 12 Aug 2008 08:28:29 EDT Biotechnology company Repros Therapeutics Inc. said Monday its second-quarter loss widened primarily on higher spending for clinical development programs. http://www.ibtimes.com/articles/20080811/repros-therapeutics-2q-loss-widens-on-costs.htm Mon, 11 Aug 2008 06:47:56 EDT Shares of Cytori Therapeutics Inc., which develops technology to preserve and develop stem cells, plunged Friday after the company reported a wider-than-expected second-quarter loss and said it would raise money with a stock sale. http://www.ibtimes.com/articles/20080808/cytori-therapeutics-shares-fall-on-wider-2q-loss.htm Fri, 08 Aug 2008 11:27:48 EDT Osiris Therapeutics Inc. reported a larger second-quarter loss Thursday, as research and development costs nearly doubled and canceled out greater revenue. http://www.ibtimes.com/articles/20080807/greater-research-costs-push-osiris-2q-loss-higher.htm Thu, 07 Aug 2008 14:12:58 EDT Drug developer Chelsea Therapeutics International said Wednesday its loss widened in the second quarter as it increased spending on research and development. http://www.ibtimes.com/articles/20080806/chelsea-therapeutics-loss-widens-in-2nd-quarter.htm Wed, 06 Aug 2008 15:50:39 EDT Acorda Therapeutics Inc. said Tuesday its second-quarter loss more than doubled as it conducted a trial of a multiple sclerosis drug candidate, and stepped up sales efforts for its muscle relaxant Zanaflex. http://www.ibtimes.com/articles/20080805/acorda-2q-loss-grows-on-selling-and-research-costs.htm Tue, 05 Aug 2008 07:27:04 EDT Cytori Therapeutics Inc., which develops technology to preserve and develop stem cells, said Monday it will sell one of its stem-cell systems to Astrea International for an undisclosed amount. http://www.ibtimes.com/articles/20080804/cytori-selling-stem-cell-system-in-singapore.htm Mon, 04 Aug 2008 13:56:05 EDT Biotechnology company CV Therapeutics Inc. said Monday the Food and Drug Administration will take longer than expected to review a request to approve its drug Ranexa as an initial treatment for angina. http://www.ibtimes.com/articles/20080728/cv-therapeutics-gets-longer-angina-drug-review.htm Mon, 28 Jul 2008 12:31:13 EDT Osiris Therapeutics Inc. said Monday it named Richard W. Hunt chief financial officer. Hunt, 53, takes over from Phil Jacoby Jr., who has served as interim CFO and corporate secretary since Cary J. Claiborne resigned as CFO in November to pursue other opportunities. http://www.ibtimes.com/articles/20080728/osiris-names-hunt-chief-financial-officer.htm Mon, 28 Jul 2008 12:41:55 EDT Biotechnology company CV Therapeutics Inc. said Thursday European regulators approved its chronic angina drug Ranexa, which is called Ranolazine outside the U.S. http://www.ibtimes.com/articles/20080710/cv-therapeutics-gets-european-ok-for-ranexa.htm Thu, 10 Jul 2008 17:03:06 EDT Biopharmaceutical company Transition Therapeutics Inc. said Thursday it named Chief Financial Officer Elie Farah to the additional role of president. The company also named Nicole Rusaw-George the company's vice president of finance. http://www.ibtimes.com/articles/20080703/transition-therapeutics-cfo-adds-president-role.htm Thu, 03 Jul 2008 08:15:27 EDT Shares of Halozyme Therapeutics Inc. rose Tuesday after the biotechnology company said its Chemophase drug candidate met safety and tolerability goals in an early-to-midstage study. http://www.ibtimes.com/articles/20080701/halozyme-shares-rise-as-drug-meets-study-goal.htm Tue, 01 Jul 2008 18:36:53 EDT Shares of Introgen Therapeutics Inc. rose Monday after the biotechnology company said it asked U.S. and European regulators to approve its drug Advexin as a head and neck cancer treatment. http://www.ibtimes.com/articles/20080630/introgen-shares-rise-on-cancer-drug-filings.htm Mon, 30 Jun 2008 20:03:26 EDT Biopharmaceutical company Bayhill Therapeutics Inc. has canceled plans for an initial public offering of common stock, according to a Securities and Exchange Commission filing on Friday. http://www.ibtimes.com/articles/20080627/bayhill-therapeutics-cancels-planned-ipo.htm Fri, 27 Jun 2008 17:42:53 EDT A director of biopharmaceutical company Halozyme Therapeutics Inc. bought 741,695 shares of stock, according to Securities and Exchange Commission filings Wednesday. http://www.ibtimes.com/articles/20080626/halozyme-therapeutics-director-kirk-buys-shares.htm Thu, 26 Jun 2008 15:30:05 EDT Biopharmaceutical company CV Therapeutics Inc. said Tuesday it has received a milestone payment of $10 million from TPG-Axon Capital related to the commercial launch of its stress agent Lexiscan. http://www.ibtimes.com/articles/20080624/cv-therapeutics-receives-10m-milestone-payment.htm Tue, 24 Jun 2008 09:47:46 EDT Aryx Therapeutics Inc. said Monday an ongoing analysis of study results for its gastrointestinal disorder treatment candidate will prevent it from attending an upcoming investor conference. http://www.ibtimes.com/articles/20080623/aryx-skipping-conference-because-of-study-analysis.htm Mon, 23 Jun 2008 17:59:12 EDT Privately held Stiefel Laboratories Inc. will buy Barrier Therapeutics Inc. for about $148 million, the companies said Monday, in a move to expand Stiefel's line of oral and topical skin treatments. http://www.ibtimes.com/articles/20080623/stiefel-laboratories-buying-barrier-therapeutics.htm Mon, 23 Jun 2008 15:17:00 EDT A Friedman Billings Ramsey analyst thinks shares of Acorda Therapeutics will stay around their current prices until early next year, when the company asks regulators to approve its multiple sclerosis drug Fampridine-SR. http://www.ibtimes.com/articles/20080623/ahead-of-the-bell-acorda-therapeutics-downgraded.htm Mon, 23 Jun 2008 11:05:24 EDT The chairman and chief executive of United Therapeutics Corp. exercised options for 7,200 shares of common stock under a prearranged trading plan, according to a Securities and Exchange Commission filing. http://www.ibtimes.com/articles/20080620/united-therapeutics-ceo-exercises-options.htm Fri, 20 Jun 2008 13:59:09 EDT